Coordinating center for the NCI small cell lung cancer research consortium

点击翻译按钮获取中文摘要

ABSTRACT The overarching goal of the NCI Small Cell Lung Cancer (SCLC) Coordinating Center has been to “break the logjam” of fundamental knowledge gaps resulting in a 30+ year lack of progress on this lethal malignancy that was designated a “recalcitrant cancer” by the US Congress and NCI. Our U24 Coordinating Center has done this by promoting and facilitating information sharing, interaction, and collaborative research among NCI- supported investigators studying SCLC. Over our initial five years of support, this Coordinating Center has significantly increased research progress within the SCLC research community through efforts including, but not limited to, the creation and ongoing expansion of comprehensive preclinical and clinical -omics databases, centralized annotation and cataloging of available SCLC models, distribution and sharing of such models, centralized data analytics, a centralized Consortium website, initiation and coordination of an interactive work- in-progress (“WIPs”) forum as well as planning and oversight of annual meetings. Of all of this, the role of the Coordinating Center in facilitating interactive WIPs (usually with ~100 attendees from dozens of institutions including patient advocates) with unprecedented information and resource sharing, has made possible tremendous progress in overcoming knowledge gaps, all of which are documented in a large number of peer reviewed publications. This renewal application will continue the exceptional research momentum the SCLC Consortium has generated, and build on this initial success through support of new initiatives. These include centralized support for databasing and comparative analysis of genetically-engineered mouse models (GEMMs), and multi-parameter characterization of patient-derived xenograft models developed across the Consortium. These additional resources will be of direct utility to the SCLC research community. As part of the U24 renewal, given the remarkable growth in scope and diversity of SCLC research, we have developed a new multi-PI structure including Charles Rudin (MSK), John Minna (UTSW), with addition of two exciting young SCLC investigators who have contributed important new insights into SCLC molecular and cellular biology - Trudy Oliver (University of Utah), and Lauren Byers (MDACC). All four have been personally very active both in the U24 activities and in their own individual SCLC U01 and R01 research. The complementary strengths of this leadership team cover all of the important areas of SCLC basic, translational, and clinical trials research. Dr. Rudin will continue as contact PI, providing administrative leadership and coordination. We emphasize that the products of the Consortium will ultimately benefit human health through fostering development of novel strategies for disease prevention, early intervention, immune surveillance, metastasis suppression, and therapeutics.